APA (7th ed.) Citation

Luangphiphat, W., Prombutara, P., Jamjuree, P., Chantarangkul, C., Vitheejongjaroen, P., Muennarong, C., . . . Taweechotipatr, M. (2025). The efficacy of Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1 probiotics in modulating gut microbiota and reducing the risk of the characteristics of metabolic syndrome: A randomized, double-blinded, placebo-controlled study. PLoS ONE, 20(1), 1. https://doi.org/10.1371/journal.pone.0317202

Chicago Style (17th ed.) Citation

Luangphiphat, Wongsakorn, Pinidphon Prombutara, Praewpannarai Jamjuree, Chantanapa Chantarangkul, Porntipha Vitheejongjaroen, Chantaluck Muennarong, Krittapat Fukfon, Manasvin Onwan, and Malai Taweechotipatr. "The Efficacy of Lacticaseibacillus Paracasei MSMC39-1 and Bifidobacterium Animalis TA-1 Probiotics in Modulating Gut Microbiota and Reducing the Risk of the Characteristics of Metabolic Syndrome: A Randomized, Double-blinded, Placebo-controlled Study." PLoS ONE 20, no. 1 (2025): 1. https://doi.org/10.1371/journal.pone.0317202.

MLA (9th ed.) Citation

Luangphiphat, Wongsakorn, et al. "The Efficacy of Lacticaseibacillus Paracasei MSMC39-1 and Bifidobacterium Animalis TA-1 Probiotics in Modulating Gut Microbiota and Reducing the Risk of the Characteristics of Metabolic Syndrome: A Randomized, Double-blinded, Placebo-controlled Study." PLoS ONE, vol. 20, no. 1, 2025, p. 1, https://doi.org/10.1371/journal.pone.0317202.